AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

12.63 +0.09 (+0.72%)

Official Closing Price Updated: 4:15 PM EDT, Oct 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript ↗

November 03, 2023

ABCL earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 02, 2023

Via Benzinga

AbCellera Reports Q3 2023 Business Results

November 02, 2023

From AbCellera Biologics Inc.

Via Business Wire

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

November 01, 2023

From AbCellera Biologics Inc.

Via Business Wire

Earnings Preview: AbCellera Biologics ↗

August 02, 2023

Via Benzinga

Recap: AbCellera Biologics Q1 Earnings ↗

May 04, 2023

Via Benzinga

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

November 01, 2023

Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader

From Prelude Therapeutics, Inc.; AbCellera

Via GlobeNewswire

AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023

October 31, 2023

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023

October 11, 2023

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces Two T-Cell Engager Presentations at SITC 2023

September 27, 2023

From AbCellera Biologics Inc.

Via Business Wire

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

Via MarketBeat

AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron

September 20, 2023

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology

September 13, 2023

From AbCellera Biologics Inc.

Via Business Wire

Why AbCellera Biologics Is Still A Buy Despite Dropping Royalties: Analyst On Long-Term Prospects ↗

August 31, 2023

Benchmark analyst Robert Wasserman reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ: ABCL),

Via Benzinga

3 AI Stocks You’ll Regret Not Buying Soon ↗

August 08, 2023

AI will have a big impact on biotech, which could help with drug discovery and create opportunities for these top AI stocks to invest in.

Via InvestorPlace

Why ResMed Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

August 04, 2023

Gainers Missfresh Limited (NASDAQ: MF) jumped 168% to $1.38 after the company announced entry of share purchase agreements for financing and business acquisition.

Via Benzinga

Apple, Fortinet, Microchip Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

August 04, 2023

U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript ↗

August 04, 2023

ABCL earnings call for the period ending June 30, 2023.

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

August 03, 2023

Via Benzinga

AbCellera Reports Q2 2023 Business Results

August 03, 2023

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing

July 24, 2023

From AbCellera Biologics Inc.

Via Business Wire

Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

July 12, 2023

Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market.

Via Benzinga

InMode, Daktronics, Domino's Pizza And Other Big Stocks Moving Higher On Wednesday ↗

July 12, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom ↗

July 08, 2023

AI is changing the face of biotechnology and drug discovery. Don't miss out on the next big boom in biotech, here are 3 stocks to consider.

Via InvestorPlace

AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023

July 06, 2023

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023

May 29, 2023

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients

May 24, 2023

From AbCellera Biologics Inc.

Via Business Wire

Why CohBar Shares Are Trading Lower By 161%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 23, 2023

Gainers

Via Benzinga

7 Growth Stocks That Could Double Your Money in 2023 ↗

May 14, 2023

For investors that really want to roll the dice, these are the enticing growth stocks that could double your money.

Via InvestorPlace

AbCellera Biologics (ABCL) Q1 2023 Earnings Call Transcript ↗

May 05, 2023

ABCL earnings call for the period ending March 31, 2023.

Via The Motley Fool

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.